Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Sodium/glucose cotransporter 2 (SGLT2) inhibitors exert important renoprotective effects in the diabetic kidney, which cannot be readily explained by their actions to lower blood glucose, blood pressure, or glomerular filtration pressures. Their effects to promote erythrocytosis suggest that these drugs act on hypoxia-inducible factors (HIFs; specifically, HIF-1α and HIF-2α), which may underlie their ability to reduce the progression of nephropathy. Type 2 diabetes is characterized by renal hypoxia, oxidative and endoplasmic reticulum stress, and defective nutrient deprivation signaling, which (acting in concert) are poised to cause both activation of HIF-1α and suppression of HIF-2α. This shift in the balance of HIF-1α/HIF-2α activities promotes proinflammatory and profibrotic pathways in glomerular and renal tubular cells. SGLT2 inhibitors alleviate renal hypoxia and cellular stress and enhance nutrient deprivation signaling, which collectively may explain their actions to suppress HIF-1α and activate HIF-2α and thereby augment erythropoiesis, while muting organellar dysfunction, inflammation, and fibrosis. Cobalt chloride, a drug conventionally classified as a hypoxia mimetic, has a profile of molecular and cellular actions in the kidney that is similar to those of SGLT2 inhibitors. Therefore, many renoprotective benefits of SGLT2 inhibitors may be related to their effect to promote oxygen deprivation signaling in the diabetic kidney.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096 · cited 1×
“counts comparable to those seen with SGLT2 inhibitors do not favorably affect the course of kidney disease.(10)”
ResultCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Appelhoff, R. J., Tian, Y.-M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., & Gleadle, J. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406026200 · Cited by 1,108 · cited 9×
“When SGLT2 is upregulated (as in type 2 diabetes), SGLT2 inhibitors block proximal tubular sodium reabsorption and thereby reduce oxygen consumption and alleviate renal hypoxia.64 As a result, these drugs may reduce the stimulus for HIF-1α production.56 The HIF-1α suppression by SGLT2 inhibitors has been proposed to u…”
BackgroundInfluentialNeuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893 · cited 1×
“Additionally, in large-scale randomized placebo-controlled clinical trials, treatment with these drugs have reduced the risk for kidney failure by ~30%.(1) These benefits were seen within 2 to 3 years of treatment and were observed in diabetic patients with both preserved and impaired glomerular function at study entr…”
BackgroundOxygen sensing requires mitochondrial ROS but not oxidative phosphorylation
Brunelle, J. K., Bell, E. L., Quesada, N. M., Vercauteren, K., Tiranti, V., Zeviani, M., Scarpulla, R. C., & Chandel, N. S. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.002 · Cited by 763 · cited 11×
“When SGLT2 is upregulated (as in type 2 diabetes), SGLT2 inhibitors block proximal tubular sodium reabsorption and thereby reduce oxygen consumption and alleviate renal hypoxia.64 As a result, these drugs may reduce the stimulus for HIF-1α production.56 The HIF-1α suppression by SGLT2 inhibitors has been proposed to u…”
BackgroundInfluentialSirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible Factor 1α
Lim, J.-H., Lee, Y.-M., Chun, Y.-S., Chen, J., Kim, J.-E., & Park, J.-W. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.023 · Cited by 758 · cited 1×
“It is therefore noteworthy that even in the presence of hypoxia, activation of both AMPK and SIRT1 inhibits HIF-1α (although studies in the kidney are limited).(53,54) However, in striking contrast, SIRT1 activates HIF-2α.”
BackgroundLuen Tang, B. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2318 · Cited by 740
Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo
Rankin, E. B., Biju, M. P., Liu, Q., Unger, T. L., Rha, J., Johnson, R. S., Simon, M. C., Keith, B., & Haase, V. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30117 · Cited by 596 · cited 1×
“This action is related to the expression of HIF2α in specialized peritubular interstitial cells in the kidney, although HIF-2α also mediates erythropoietin synthesis in the liver.(13,14) In contrast, although HIF-1α can influence erythropoiesis if HIF-2α signaling is impaired, HIF-1α primarily activates the transcript…”
BackgroundRoxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813599 · Cited by 582
Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483 · cited 1×
“80 does not prevent kidney injury.(6) Furthermore, SGLT2 inhibitors exert renal benefits in patients with glomerular filtration rates that are low enough to negate the ability of these drugs to cause glycosuria and decrease glomerular filtration pressures.”
BackgroundMazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044235 · Cited by 371
van Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.013 · Cited by 363
Impaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy
Tagawa, A., Yasuda, M., Kume, S., Yamahara, K., Nakazawa, J., Chin-Kanasaki, M., Araki, H., Araki, S.-I., Koya, D., Asanuma, K., et al. (2016) · Diabetes · doi:10.2337/db15-0473 · Cited by 315
Lenoir, O., Jasiek, M., Hénique, C., Guyonnet, L., Hartleben, B., Bork, T., Chipont, A., Flosseau, K., Bensaada, I., Schmitt, A., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1049799 · Cited by 296
Autophagy in diabetic kidney disease: regulation, pathological role and therapeutic potential
Yang, D., Livingston, M. J., Liu, Z., Dong, G., Zhang, M., Chen, J.-K., & Dong, Z. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2639-1 · Cited by 252 · cited 1×
“The suppression of SIRT1/AMPK activation can directly promote mitochondrial dysfunction, oxidative stress, and proinflammatory pathways,(47,48) and downregulation of SIRT1/AMPK also eliminates a major stimulus to autophagic flux.(41,46) For these reasons, suppression of SIRT1/AMPK signaling and autophagy appear to con…”
BackgroundOjima, A., Matsui, T., Nishino, Y., Nakamura, N., & Yamagishi, S. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1395609 · Cited by 223
Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury
Hong, Q., Zhang, L., Das, B., Li, Z., Liu, B., Cai, G., Chen, X., Chuang, P. Y., He, J. C., & Lee, K. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.008 · Cited by 222 · cited 6×
“Exaggerated oxidative stress has been directly implicated in the dysfunction and demise of both podocytes and renal tubular cells, as well as the stimulation of proinflammatory pathways, thus contributing to the pathogenesis of diabetic CKD.42 Importantly, reactive oxygen species are an important stimulus to HIF-1α ac…”
BackgroundInfluentialLiu, W. J., Shen, T. T., Chen, R. H., Wu, H.-L., Wang, Y. J., Deng, J. K., Chen, Q. H., Pan, Q., Huang Fu, C.-M., Tao, J.-L., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.666354 · Cited by 132
Layton, A. T., & Vallon, V. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00551.2017 · Cited by 132
Wang, J., Chen, Y., Xu, W., Lu, N., Cao, J., & Yu, S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0215362 · Cited by 45 · cited 1×
“because even intensive control of blood pressure does not prevent serious renal events in type 2 diabetes.(3) SGLT2 inhibitors alleviate the increased intraglomerular filtration pressure that has been implicated in the genesis of”
BackgroundKidney hemodynamics after ketone body and amino acid infusion in normal and IDDM subjects
Nosadini, R., Trevisan, R., Fioretto, P., Semplicini, A., Samà, B., Velussi, M., Luigi Da Campo, G., Avogaro, A., Vizzaccaro, A., Donadon, V., et al. (1989) · Diabetes · doi:10.2337/diab.38.1.75 · Cited by 34
Cited by
Yang, Z., Li, T., Xian, J., Chen, J., Huang, Y., Zhang, Q., Lin, X., Lu, H., & Lin, Y. (2022) · The FASEB Journal · doi:10.1096/fj.202200243r · Cited by 79
Persson, F., Rossing, P., Vart, P., Chertow, G. M., Hou, F. F., Jongs, N., McMurray, J. J. V., Correa-Rotter, R., Bajaj, H. S., Stefansson, B. V., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0300 · Cited by 78
“hemoglobin and hematocrit may reflect improvement in renal hypoxia and restoration in the hypoxia-inducible factor 1a/2a balance, stimulating erythropoiesis and reducing inflammation (7).”
BackgroundIschemia-reperfusion injury in kidney transplantation: mechanisms and potential therapeutic targets
Lasorsa, F., Rutigliano, M., Milella, M., d’Amati, A., Crocetto, F., Pandolfo, S. D., Barone, B., Ferro, M., Spilotros, M., Battaglia, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084332 · Cited by 74
Pathogenesis of diabetic complications: Exploring hypoxic niche formation and HIF-1α activation
Bi, J., Zhou, W., & Tang, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116202 · Cited by 19
Metadata
- Authors
- Packer, M.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 77
- Issue
- 2
- Pages
- 280-286
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W3044410554
- Cited by
- 214
- References
- 24
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.